This phase I/II trial is trying to determine whether it is safe to give the study drug (BMS-986249), alone and in combination with an immunotherapy (Nivolumab), to patients with advanced solid cancers.
This trial is treating patients with advanced solid cancers.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
Bristol-Myers Squibb (BMS)
This is a non-randomised trial. Patients will receive specified doses of BMS-986249 with or without Nivolumab on specified days.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More